baseimmune is a biotech startup founded to create the next generation of vaccines. Our unique platform is based on innovative and powerful technology which is able to generate antigens using a level of informatics depth not previously seen. Using this approach we are able to tackle emerging and challenging pathogens that had been failed by traditional approaches and importantly able to ensure our vaccines remain effective even if a pathogen mutates. As a discovery phase biotech, we offer our antigen discovery services and develop broad-spectrum vaccines against highly variable pathogens.
baseimmune’s technology harnesses pathogen and epidemiology big data combined with biological expertise to devise a robust method for antigen discovery, one of the major roadblocks in vaccine development. By streamlining the antigen selection process, we can develop better vaccines and empower agriculture and public health to stop emerging dangerous pathogens from spreading.
Total Funding: 20,000,000
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2019
Feb 2024
- Baseimmune Raises £9M in Series A funding to Develop Better Vaccines Faster
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Baseimmune
Bioinformatician
London, England
Head of Operations
London, England
Scientist
London, England
